Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kuros Biosciences

Explore full profile

Biologic implants to promote bone healing in spinal and orthopaedic surgery

Zurich, SwitzerlandFounded 2000Biotech & Life Sciences
Valuation $752M Market cap · 2026
Revenue $152M Latest reported FY
EBITDA $17M Latest reported FY

About Kuros Biosciences

Kuros Biosciences AG is a pioneering company in the field of bone healing and regeneration. The company specializes in developing advanced bone graft solutions that target and control bone healing processes. Kuros primarily serves healthcare providers, including hospitals and clinics, focusing on patients requiring bone grafts for spinal fusion and other orthopedic procedures. Operating in the medical technology market, Kuros leverages its proprietary technologies to create products like MagnetOs and Fibrin PTH, which are designed to improve patient outcomes by enhancing bone healing and reducing the risk of non-unions.

The business model of Kuros revolves around research and development, clinical trials, and commercialization of its innovative bone graft products. Revenue is generated through the sale of these products to healthcare institutions and through partnerships with other medical technology companies. Kuros also invests in continuous research to validate the efficacy and safety of its products, ensuring they meet the highest standards of medical care.

Kuros operates in a highly specialized niche within the broader medical technology sector, focusing on bone grafting solutions that offer significant advantages over traditional methods. The company's commitment to innovation and patient care positions it as a leader in the field of bone healing.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2000
Headquarters
Zurich, Switzerland
Listing
IPO 2016
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Venture Incubator,
  • VI Partners
  • CDC Innovation
  • Innovation Capital
  • DEFI Gestion
  • NeoMed
  • Vinci Capital
  • CDC Enterprises
  • Reference Capital

Series B and later5 investors entered at this stage

  • Omega Funds
  • Swiss Helvetia Fund
  • EQT Life Sciences
  • ZKB - Zürcher Kantonalbank
  • Nice&Green SA

Talent

Book a demo to see the people
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇺🇸 United States51%
🇳🇱 Netherlands39.9%
🇨🇭 Switzerland5.9%
🇬🇧 United Kingdom2%
🇦🇺 Australia0.7%
Top 5 of 6 shown

Patents

Estimated portfolio value
$20M

9 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kuros Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kuros Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles